Literature DB >> 16961139

Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors.

Abdeljabar El Andaloussi1, Yu Han, Maciej S Lesniak.   

Abstract

OBJECT: Regulatory CD4+CD25+ T cells have been shown to play an important role in the regulation of the immune response. Whereas the presence of these cells has been associated with immune suppression, the lack of regulatory T (Treg) cells has been shown to induce autoimmunity. The purpose of this study was to define the role of Treg cells in tumors of the central nervous system (CNS).
METHODS: The authors implanted syngeneic GL261 tumor cells in the brains or flanks of C57BL/6 mice. The resulting tumors were later removed at specific time points, and the presence of tumor-infiltrating lymphocytes was analyzed by performing flow cytometry for the presence of Treg cells. In a separate experiment, mice with GL261 tumors were treated with injections of anti-CD25 monoclonal antibody (mAb) to determine whether depletion of Treg cells may have an impact on the length of survival in mice with brain tumors. Tumor-infiltrating lymphocytes isolated from mice with GL261 tumors were found to have a significant increase in the presence of Treg cells compared with control lymphocytes (p < 0.05). Moreover, Treg cells isolated in murine brain tumors expressed FoxP3, CTLA-4, and CD62L. Mice treated with anti-CD25 mAb lived significantly longer than tumor-bearing control animals (p < 0.05). An analysis of brains in surviving animals showed a depletion of CD4+CD25+ T cells.
CONCLUSIONS: The results of this study indicate that CD4+CD25+ Treg cells play an important role in suppressing the immune response to CNS tumors. These Treg cells may therefore represent a potentially novel target for immunotherapy of malignant gliomas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16961139     DOI: 10.3171/jns.2006.105.3.430

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  71 in total

Review 1.  Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets.

Authors:  Peter J Bugelski; Pauline L Martin
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 2.  The Gut-Brain Axis, Paving the Way to Brain Cancer.

Authors:  Ruty Mehrian-Shai; Juergen K V Reichardt; Curtis C Harris; Amos Toren
Journal:  Trends Cancer       Date:  2019-03-16

Review 3.  Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium.

Authors:  Melissa L Bondy; Michael E Scheurer; Beatrice Malmer; Jill S Barnholtz-Sloan; Faith G Davis; Dora Il'yasova; Carol Kruchko; Bridget J McCarthy; Preetha Rajaraman; Judith A Schwartzbaum; Siegal Sadetzki; Brigitte Schlehofer; Tarik Tihan; Joseph L Wiemels; Margaret Wrensch; Patricia A Buffler
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

Review 4.  The effects of immunosuppression on regulatory CD4(+)CD25(+) T cells: impact on immunosuppression selection in transplantation.

Authors:  Aqeel Javeed; Yong Zhao
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

5.  Inflammation and Gliomagenesis: Bi-Directional Communication at Early and Late Stages of Tumor Progression.

Authors:  Rui Pedro Galvão; Hui Zong
Journal:  Curr Pathobiol Rep       Date:  2013-03-01

6.  A Combination of Systemic and Intracranial Anti-CD25 Immunotherapy Elicits a Long-Time Survival in Murine Model of Glioma.

Authors:  Marie-Denise Poirier; Houda Haban; Abdeljabar El Andaloussi
Journal:  J Oncol       Date:  2010-03-21       Impact factor: 4.375

7.  The presence of IL-17A and T helper 17 cells in experimental mouse brain tumors and human glioma.

Authors:  Derek A Wainwright; Sadhak Sengupta; Yu Han; Ilya V Ulasov; Maciej S Lesniak
Journal:  PLoS One       Date:  2010-10-23       Impact factor: 3.240

8.  The role of regulatory T cells in cancer.

Authors:  Tai-You Ha
Journal:  Immune Netw       Date:  2009-12-31       Impact factor: 6.303

9.  Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody.

Authors:  Bryan D Choi; Patrick C Gedeon; James E Herndon; Gary E Archer; Elizabeth A Reap; Luis Sanchez-Perez; Duane A Mitchell; Darell D Bigner; John H Sampson
Journal:  Cancer Immunol Res       Date:  2013-09       Impact factor: 11.151

10.  Dynamics of central and peripheral immunomodulation in a murine glioma model.

Authors:  Benjamin C Kennedy; Lisa M Maier; Randy D'Amico; Christopher E Mandigo; Elizabeth J Fontana; Allen Waziri; Marcela C Assanah; Peter Canoll; Richard C E Anderson; David E Anderson; Jeffrey N Bruce
Journal:  BMC Immunol       Date:  2009-02-18       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.